Please take a few minutes to log in to BIO’s FDA survey and provide feedback on your company’s interactions with FDA.
PDUFA 6 negotiations are ongoing. As BIO continues its technical discussions with the FDA, we can help to ensure these vital conversations are reflective of biotech company experiences and a success for the industry.
Please take a few minutes to log in to BIO’s FDA survey and provide feedback on your company’s interactions with FDA.
Communications between drug sponsors and drug reviewers will be a key focus of PDUFA 6, and our negotiators need all the phase-specific data possible to support BIO’s case. Our survey allows you to provide phase-specific, anonymous feedback on your interactions with FDA for each program your company has in the clinic.
Your input on FDA review divisions, communication channels, and specialized approval pathways is crucial to the success of the PDUFA negotiations.
Visit fdasurvey.bio.org to get started today!